Trikafta
Cystic fibrosis medicine
1 conceptTRIKAFTA is Vertex's triple-combination CFTR modulator therapy for eligible people with cystic fibrosis.
ProductsVertex Pharmaceuticals
Vertex Pharmaceuticals product analyses
A tighter look at the products that matter most to Vertex Pharmaceuticals, along with the free, open, decentralized, or cooperative alternatives already creating pricing pressure and the original disruption concepts that could widen that pressure further.
Products
Where the moat actually touches users
These pages zoom into the products and services that matter most to each company, the alternatives already nibbling at them, and 2 structured disruption concepts across the current product set.
2 disruption concepts tracked0 documented exceptions
Casgevy
Gene-edited cell therapy
1 conceptCASGEVY is a CRISPR-based autologous cell therapy for eligible patients with sickle cell disease or transfusion-dependent beta thalassemia.
Paper trail
Company-level source stack
These sources shaped the scoring and writing. The site is opinionated, but it should not behave like it is improvising facts in a dark room.
Vertex Reports Fourth Quarter and Full Year 2025 Financial Results
Vertex Pharmaceuticals · investor relations
Provides 2025 revenue, product revenue mix, launch commentary, and profitability context.
Reviewed 2026-05-27
Vertex Pharmaceuticals 2025 Form 10-K
U.S. Securities and Exchange Commission · regulatory filing
Primary filing source for business description, risks, product revenue, net income, and regulated operating model.
Reviewed 2026-05-27
Vertex Pharmaceuticals Form 10-Q for the Quarter Ended March 31, 2026
Vertex Pharmaceuticals · regulatory filing
Updates 2026 product revenue mix and early CASGEVY/JOURNAVX contribution after the 2025 annual report.
Reviewed 2026-05-27
Vertex Pharmaceuticals Market Cap
StockAnalysis · market data
Point-in-time market capitalization reference around the May 2026 index refresh window.
Reviewed 2026-05-27